Back to News
Market Impact: 0.25
Vaxcyte, Inc. Reports Third Quarter 2026 Financial Results and VAX-31 Clinical Progress
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Vaxcyte reported a net loss of $297.1 million for the third quarter ended September 30, 2026, up from $212.8 million in the year-earlier quarter. The company also provided clinical-pipeline updates, but the available article text contains no details on those updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
PCVX-0.20
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook